Skip to main content

Vitamin D Supplementation Cuts Respiratory Infections


 
August 20, 2012 — Supplementing vitamin D in the diets of school children may cut the incidence of acute respiratory infections (ARIs) by as much as half, according to results from a randomized controlled trial carried out in Mongolia.
"This double-blinded [randomized controlled trial] of Mongolian children in winter found that vitamin D3supplementation with only 300 IU daily led to a clinically and statistically significant reduction in risk of parent-reported ARIs," Carlos Camargo Jr, MD, DrPH, from the Harvard School of Public Health, Boston, Massachusetts, and colleagues write in their article, published online August 20 in Pediatrics.
The authors note that a growing number of epidemiologic studies link vitamin D deficiency to heightened risk for ARIs. Other studies have suggested that supplementing vitamin D might cut risks for ARIs and also influenza, but results from those trials have not been consistent.
To find out more, Dr. Camargo and colleagues studied a cohort of 247 children in the central Asian country of Mongolia, where temperatures during much of the year keep residents bundled against the cold and their skin lacking in exposure to sunlight. The human body synthesizes vitamin D when the skin is exposed to sunlight.
In this study of third- and fourth-grade students, carried out from January to March 2009, investigators randomly assigned the children to 1 of 2 groups. The first group (143 children) received milk each day that was fortified with 300 IU of vitamin D3<. The other group (104 children) received milk without vitamin D added.
Vitamin D serum levels were checked both at the beginning of the study and again at the end. Parents then were asked how many ARIs their children had experienced during the previous 3 months.
The researchers report that at baseline, the children's median serum 25(OH)D level was 7 ng/mL, but after the 3-month intervention, there was a significant difference in the 2 groups. Although the control group's vitamin D levels remained at 7 ng/mL, levels in the children who received fortified milk nearly tripled, rising to 19 ng/mL.
That difference appeared to have carried over in numbers of ARIs. "Compared with controls, children receiving vitamin D reported significantly fewer ARIs during the study period (mean: 0.80 vs 0.45; P = .047), with a rate ratio of 0.52 (95% confidence interval: 0.31–0.89)," the authors write. "Adjusting for age, gender, and history of wheezing, vitamin D continued to halve the risk of ARI (rate ratio: 0.50 [95% confidence interval: 0.28–0.88])."
The researchers say they saw similarly positive results when they assessed children whose vitamin D levels at baseline had been either below or above the median.
Although the researchers acknowledge that the Mongolian city where the study was carried out, Ulaanbaatar, is situated at a fairly high latitude (48 degrees north), they point out that Montreal and Paris are both at similar latitudes, and many major North American and European are even farther north.
The authors have disclosed no financial conflicts of interest related to this study.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...
4 comments
Read more